Eli Lilly Dips 2.3% Friday, But Analysts Boost Targets to as High as $1,370

Eli Lilly (LLY) closed Friday, July 10, 2026, at $1,188.58, down $28.37, or 2.33%, from the prior day's close of $1,216.95. The stock opened at $1,210.31, hit an intraday high of $1,212.96, and a low of $1,178.32^[CNN]. U.S. markets were closed Monday, July 13, for a holiday, so the stock remains at that level with no intraday movement. Despite Friday's pullback, several Wall Street analysts issued positive rating adjustments on the stock last week.

Analysts Raise Targets, BofA and Truist Turn Bullish

Even as Lilly's stock pulled back, multiple Wall Street firms updated their views on the stock last week. According to TipRanks, BofA raised its price target on Lilly to $1,334 from $1,251 on July 10^[TipRanks]. Prior to that, Truist lifted its target to $1,370 from $1,281 on July 9^[TipRanks]. Both targets are well above the current closing price of $1,188.58, signaling analyst optimism on Lilly's long-term prospects.

Separately, multiple firms published reports on July 9 covering healthcare names including Lilly and AbbVie (ABBV)^[TipRanks]. Another report on the same day covered analyst views on Lilly and Alnylam Pharma (ALNY)^[TipRanks].

Pipeline Progress: Alzheimer's and Eczema Updates

On the R&D front, Lilly has several recent developments. According to TipRanks, the company will present abstracts from its Kisunla Alzheimer's disease trials at the 2026 AAIC^[TipRanks]. Kisunla is a key product in Lilly's Alzheimer's portfolio, and the data presentation at AAIC could provide new efficacy and safety information to the market.

Meanwhile, Lilly's eczema treatment received a positive recommendation in Canada. According to TipRanks, the favorable review is seen as a positive catalyst for the stock^[TipRanks]. Additionally, Lilly is advancing a Phase 2 clinical trial for neuropathic pain that is nearing completion^[TipRanks].

Market Position and Valuation: Mega-Cap, Near 52-Week High

According to CNN Markets, Lilly's current market cap is approximately $1.12 trillion, placing it in mega-cap territory. Its momentum indicators show the stock trading near the top of its 52-week range and above its 200-day simple moving average^[CNN]. Key valuation metrics such as the P/E ratio are also available on CNN Markets, though specific figures were not provided in the excerpt. Information on Lilly's next quarterly earnings report, dividend yield, ex-dividend date, and dividend payment date can also be found on the CNN Markets page^[CNN].

Industry Background: Healthcare Executive Churn

In the broader healthcare sector, executive turnover has been notable recently. According to Fierce Biotech, Swiss pharmaceutical company Idorsia has appointed Roland Wandeler as its new CEO, effective October 1, following the departure of its previous CEO^{[Fierce Biotech]}. Meanwhile, Idorsia's former CEO Srishti Gupta has joined Maryland-based NovaBridge BioSciences as CEO^{[Fierce Biotech]}. Separately, Sofinnova Partners announced the appointment of David Evans as a partner, though this is unrelated to Lilly. These moves reflect active talent flows within the biotech and pharmaceutical industries.

This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.